Stephanie Baum , 2025-05-06 11:30:00
Gaining greater insight into the patient journey from diagnosis through treatment is of great interest to drug developers as they aspire to produce more effective drugs. Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access.
The webinar will include executives from PurpleLab and Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech’s gCS Computational Catalysts. Genentech is owned by Roche.
Among the talking points the webinar will cover are:
- How can RWD be leveraged by pharma companies for the NSCLC patient journey?
- What does the “typical” patient journey for NSCLC look like?
- Mapping the nuanced parts of a patient’s journey
- The value of leveraging Social Determinants of Health data
- Addressing socioeconomic barriers that may hinder clinical trial participation
- Using RWD to improve clinical trial recruitment, clinical endpoints, and inform market access strategies
To register for the webinar Eliminating Blind Spots in the Patient Journey, scheduled for 1-2 pm ET on May 22, please fill out the form below:
Photo: Eugene Mymrin, Getty Images
